Graziano Seghezzi

Graziano is a managing partner at Sofinnova Partners and an active member of the investment team in the Sofinnova Capital Funds. Graziano serves on the Board of Directors of several companies he helped create and finance, including EryDel, Hotspot Therapeutics, Enthera, and Genespire, and Inotrem. He is responsible for a number of substantial exits, including Corvidia Therapeutics, which was sold to Novo Nordisk for €2.1 billion in 2020; Breathe Therapeutics sold to Zambon in 2019; Hookipa Pharma, floated on the Nasdaq in 2019; GlycoVaxyn sold to GlaxoSmithKline in 2015.

Graziano holds a degree in genetics and microbiology from the University of Pavia, Italy, and an MBA from RSM-Erasmus University, The Netherlands. He conducted academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases.